Compound class:
Synthetic organic
Comment: Naphthoquine is a 4-aminoquinoline antimalarial compound.
The marketed formulations contain naphthoquine phosphate (PubChem CID 9851774). The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. |
|
No information available. |
Summary of Clinical Use ![]() |
Naphthoquine does not have FDA or EMA approval but in combination with artemisinin (trade name ARCO®) is one of the new artemisinin-based combination therapies (ACTs) registered and used in a number of countries but not yet recommended by the WHO [4]. A Phase 4 trial to evaluate ARCO® for the treatment of uncomplicated P. falciparum malaria in adults and children has been completed (NCT01930331). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01930331 | Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO | Phase 4 Interventional | Ifakara Health Institute |